SCHEMBL9934561

SCHEMBL9934561

CC(C)CC(C)Nc1ccc(Nc2ccc(NC(C)C)cc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.76
CYP3A4 P08684 3/20 0.76
ALOX15 P16050 3/20 0.76
TSHR P16473 3/20 0.76
HSD17B10 Q99714 3/20 0.76
ALOX12 P18054 2/20 0.76
HIF1A Q16665 2/20 0.76
MAPK1 P28482 2/20 0.76
TDP1 Q9NUW8 5/20 0.59
L3MBTL1 Q9Y468 4/20 0.59
THRB P10828 3/20 0.59
RECQL P46063 3/20 0.59
LMNA P02545 2/20 0.59
ATM Q13315 1/20 0.59
TP53 P04637 1/20 0.48
HSP90AA1 P07900 1/20 0.48
CASP1 P29466 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
RXFP1 Q9HBX9 1/20 0.37
KCNH3 Q9ULD8 7/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9933293 0.94 ALDH1A1 (0.85) ALDH1A1CYP3A4ALOX15TSHRHSD17B10
SCHEMBL6328763 0.93 ALDH1A1 (0.90) ALDH1A1CYP3A4ALOX15TSHRHSD17B10
SCHEMBL144947 0.87 ALDH1A1 (0.73) ALDH1A1CYP3A4ALOX15TSHRHSD17B10
SCHEMBL2720733 0.86 ALDH1A1 (0.73) ALDH1A1CYP3A4ALOX15TSHRHSD17B10
SCHEMBL39447 0.86 ALDH1A1 (1.00) ALDH1A1CYP3A4ALOX15TSHRHSD17B10
SCHEMBL15476044 0.86 ALDH1A1 (1.00) ALDH1A1CYP3A4ALOX15TSHRHSD17B10
SCHEMBL31215174 0.86 ALDH1A1 (1.00) ALDH1A1CYP3A4ALOX15TSHRHSD17B10
SCHEMBL16962433 0.85 ALDH1A1 (0.71) ALDH1A1CYP3A4ALOX15TSHRHSD17B10
SCHEMBL9934007 0.82 TDP1 (0.81) ALDH1A1CYP3A4ALOX15TSHRHSD17B10
SCHEMBL25411983 0.82 ALDH1A1 (0.67) ALDH1A1CYP3A4ALOX15TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835687-B2 Method for preparation of 4,4′-dinitrodiphenylamine and 4,4′-bis(alkylamino)diphenylamine with the base catalyst complex KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) 2014-09-16 US disclosed
US-8759587-B2 Method for preparation of 4,4′-dinitrodiphenylamine and 4,4′-bis(alkylamino)diphenylamine by using 4-nitroaniline KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) 2014-06-24 US disclosed
US-20120197044-A1 PRODUCTION METHOD FOR 4,4'-BIS(ALKYLAMINO) DIPHENYLAMINE KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) 2012-08-02 US disclosed
US-20120157713-A1 METHOD FOR PREPARATION OF 4,4'-DINITRODIPHENYLAMINE AND 4,4'-BIS(ALKYLAMINO)DIPHENYLAMINE WITH THE BASE CATALYST COMPLEX KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) 2012-06-21 US disclosed
US-20120157714-A1 METHOD FOR PREPARATION OF 4,4'-DINITRODIPHENYLAMINE AND 4,4'-BIS(ALKYLAMINO)DIPHENYLAMINE BY USING 4-NITROANILINE KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157714-A1 METHOD FOR PREPARATION OF 4,4'-DINITRODIPHENYLAMINE AND 4,4'-BIS(ALKYLAMINO)DIPHENYLAMINE BY USING 4-NITROANILINE NAAA, AADAT, HPD ALDH1A1 429/4885CYP3A4 37/4885ALOX15 1089/4885
US-20120157713-A1 METHOD FOR PREPARATION OF 4,4'-DINITRODIPHENYLAMINE AND 4,4'-BIS(ALKYLAMINO)DIPHENYLAMINE WITH THE BASE CATALYST COMPLEX NAAA, HNF4A, ABAT ALDH1A1 845/4885CYP3A4 157/4885ALOX15 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.